Abstract 5771
Background
Hyponatremia, usually defined as the sodium serum level < 135 mEq/l (mmol/l), is a common electrolyte disorder in the clinical practice.1 Despite its often benign course, it can rapidly evolve into a life threatening condition mainly due to neurological symptoms. Moreover, in cancer patients, hyponatremia is significantly associated with reduced overall survival.2 In cancer patients hyponatremia can occur due to malignancy as well as chemotherapy.3 Many chemotherapy drugs have been reported to induce hyponatremia.4 This study aims to determine which chemotherapeutic drugs used in hematological patients are mostly associated with hyponatremia.
Methods
This study analyzed retrospectively the data from 189 patients with diagnosed haematological malignancies that developed hyponatremia while undergoing chemotherapy. The period of observation was determined to start at the first day of a chemotherapy cycle until the 3rd day after the end of a cycle. For the purpose of this study, hyponatremia was defined as serum sodium level < 135 mEq/l (mmol/l).
Results
In our cohort of 189 patients with hyponatremia the most predominant hematological malignancy was Multiple Myeloma, which was present in 56 (29.6%) of the included patients and was followed by diffuse large B-cell Lymphoma with 34 (13.2%) patients. The median age of the studied cohort was 68 years (range 33-84 years).The mean value of serum sodium was 130.4 ± 0.27 mEq/l. 42 (22.4 %) patients had hyponatremia in the 4th cycle of the chemotherapy, with 101 (53.4%) patients developing hyponatremia in the first 4 cycles of the chemotherapy. From all patients with hyponatremia (n = 189), 43 (22.7%) received Cyclophosphamide, 38 (20.1%) Vincristine, 85 (44.9%) Cyclophosphamide and Vincristine as part of a combination, 20 (10.5%) Methothrexate, 18 (9.5%) Cisplatin and 8 (4.2%) Daratumumab.
Conclusions
Patient with hematological malignancies are at increased risk of hyponatremia possibly induced by chemotherapy. The combination regimens seem to increase the risk of developing hyponatremia substantially. In which way the occurrence of hyponatremia depends on cofactors such as infusion schemas or tumor lysis has to be evaluated in prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5939 - Matrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer
Presenter: Olga Simonova
Session: Poster Display session 1
Resources:
Abstract
2703 - Uveal melanoma cell lines depend on multiple signaling pathways for survival
Presenter: John Park
Session: Poster Display session 1
Resources:
Abstract
4849 - XAF1 and ZNF313 complex stimulates ER stress-induced apoptosis via direct GRP78 inhibition.
Presenter: Sungchan Jang
Session: Poster Display session 1
Resources:
Abstract
4801 - XAF1 assembles a destructive complex to induce BRCA1-mediated apoptosis via suppressing ERa and switching estrogen function
Presenter: Seung-hun Jang
Session: Poster Display session 1
Resources:
Abstract
3416 - Cancer associated fibroblasts promote cancer progression via Wnt2 secretion in colorectal cancer
Presenter: Hideaki Karasawa
Session: Poster Display session 1
Resources:
Abstract
4273 - Paired-related homeobox 1 overexpression promotes invasion and metastasis and is a prognostic factor for worse disease-free survival in patients with lung cancer
Presenter: Jung-jyh Hung
Session: Poster Display session 1
Resources:
Abstract
4241 - LncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin
Presenter: Xin Guo
Session: Poster Display session 1
Resources:
Abstract
5388 - GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
5208 - Characterisation of growth hormone signal transduction in primary melanoma cell lines
Presenter: Karla Sousa
Session: Poster Display session 1
Resources:
Abstract
3156 - LAPTM5 protein can regulate TGF-β mediated MAPK and Smad signaling pathways in ovarian cancer cell
Presenter: Yan Gao
Session: Poster Display session 1
Resources:
Abstract